{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:41:23Z","timestamp":1780051283255,"version":"3.53.1"},"reference-count":31,"publisher":"Societatea Romana de Morfologie","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:p>Patients with lung cancer commonly report a broad spectrum of symptoms driven by both side effects of treatment and aggressive progression of disease. As a result, growing evidence indicates that pulmonary rehabilitation (PR) can meaningfully improve exercise performance, health-related quality of life (QoL), fatigue, and dyspnea. The core objective of any PR program is to improve the patient\u2019s overall functional profile. In this study conducted at the Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania, we assessed the functional profile of patients with non-small cell lung cancer (NSCLC) \u2013 specifically lung adenocarcinoma (LUAD) and squamous cell carcinoma (SCC) \u2013 and explored its relationship with key biomarkers: programmed death-ligand 1 (PD-L1), anaplastic lymphoma kinase (ALK), and epidermal growth factor receptor (EGFR). Functional status was evaluated using the International Classification of Functioning, Disability, and Health\u2013Rehabilitation Core Set (ICF\u2013RCS). Exercise capacity was measured with the 6-Minute Walk Distance (6MWD) test, health-related QoL was evaluated using the validated European Organization for the Research and Treatment of Cancer Core Quality of Life 30-item Questionnaire (EORTC QLQ-C30) questionnaire and anxiety levels were assessed with the Generalized Anxiety Disorder 7-item (GAD-7) instrument. The study identified a correlation between the patients\u2019 functional profiles and specific biomarker patterns. Based on these findings, we believe that incorporating biomarker information into functional evaluation could help build a clearer and more clinically relevant understanding of patient needs during PR, ultimately contributing to more personalized comprehensive care. We propose that future research should examine whether the relationship between biomarker status and functional, psychological, and QoL outcomes remains consistent following a structured rehabilitation program, and whether these biological markers can predict which patients are most likely to experience functional and emotional improvements. Such insight could prove valuable in guiding individualized rehabilitation strategies for patients with NSCLC.<\/jats:p>","DOI":"10.47162\/rjme.66.4.10","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:10:17Z","timestamp":1774865417000},"page":"719-726","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the functional profile of bronchopulmonary cancer patients based on biomarkers in relation to the International Classification of Functioning, Disability and Health"],"prefix":"10.47162","volume":"66","author":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, Romania; Department of Pneumology, Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania-Ioana","family":"Goncea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara Amalia","family":"B\u0103lteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pneumology, Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania; Department of Pneumology, Faculty of Medicine, Titu Maiorescu University, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela-\u015etefania","family":"Marghescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pathology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Research, Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pneumology, Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania; Department of Pneumology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena Rodica","family":"Tr\u0103istaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Physical Medicine and Rehabilitation, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26736","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"ref0","unstructured":"\"[1] World Health Organization (WHO)\/International Agency for Research on Cancer (IARC). Global Cancer Observatory: cancer today. WHO, IARC, Lyon, France, accessed on 18 July 2024."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, Bonaventure A, Valkov M, Johnson CJ, Est\u00e8ve J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125):1023-1075. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3","DOI":"10.1016\/S0140-6736(17)33326-3"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med, 2020, 41(1):1-24. https:\/\/doi.org\/10.1016\/j.ccm.2019.10.001","DOI":"10.1016\/j.ccm.2019.10.001"},{"key":"ref3","unstructured":"[4] Travis WD, Brambilla E, M\u00fcller-Hermelink HK, Harris CC (eds). Pathology and genetics of tumours of the lung, pleura, thymus and heart. World Health Organization (WHO) Classification of Tumours, 3rd edition, vol. 10, International Agency for Research on Cancer (IARC) Press, Lyon, France, 2004."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JHM, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 2011, 6(2):244-285. https:\/\/doi.org\/10.1097\/JTO.0b013e318206a221","DOI":"10.1097\/JTO.0b013e318206a221"},{"key":"ref5","unstructured":"[6] National Cancer Institute (NCI). Non-small cell lung cancer treatment (PDQ\u00ae) - health professional version. U.S. Department of Health and Human Services, National Institutes of Health (NIH), Bethesda, MD, USA, accessed on 18 July 2024."},{"key":"ref6","unstructured":"[7] Tomashefski JF Jr, Connors AF Jr, Rosenthal ES, Hsiue IL. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med, 1990, 114(5):468-474."},{"key":"ref7","unstructured":"[8] Kumar V, Abbas AK, Aster JC. Robbins basic pathology. 9th edition. Elsevier-Saunders, Philadelphia, PA, USA, 2013."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000, 100(1):57-70. https:\/\/doi.org\/10.1016\/s0092-8674(00)81683-9","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 1990, 61(5):759-767. https:\/\/doi.org\/10.1016\/0092-8674(90)90186-i","DOI":"10.1016\/0092-8674(90)90186-I"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heel of cancer. Science, 2002, 297(5578):63-64. https:\/\/doi.org\/10.1126\/science.1073096","DOI":"10.1126\/science.1073096"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol, 2011, 12(2):175-180. https:\/\/doi.org\/10.1016\/S1470-2045(10)70087-5","DOI":"10.1016\/S1470-2045(10)70087-5"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018, 29(Suppl 4):iv192-iv237. https:\/\/doi.org\/10.1093\/annonc\/mdy275","DOI":"10.1093\/annonc\/mdy275"},{"key":"ref13","unstructured":"[14] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 11.2024. NCCN, Plymouth Meeting, PA, USA, accessed on 18 July 2024."},{"key":"ref14","unstructured":"[15] World Health Organization (WHO). International Classification of Functioning, Disability and Health (ICF). WHO, Geneva, Switzerland, accessed on 18 July 2024."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2015, 2:CD003793. https:\/\/doi.org\/10.1002\/14651858.CD003793.pub3","DOI":"10.1002\/14651858.CD003793.pub3"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Shannon VR. Role of pulmonary rehabilitation in the management of patients with lung cancer. Curr Opin Pulm Med, 2010, 16(4):334-339. https:\/\/doi.org\/10.1097\/MCP.0b013e32833a897d","DOI":"10.1097\/MCP.0b013e32833a897d"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Stout NL, Santa Mina D, Lyons KD, Robb K, Silver JK. A systematic review of rehabilitation and exercise recommendations in oncology guidelines. CA Cancer J Clin, 2021, 71(2):149-175. https:\/\/doi.org\/10.3322\/caac.21639","DOI":"10.3322\/caac.21639"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med, 2002, 166(1):111-117. https:\/\/doi.org\/10.1164\/ajrccm.166.1.at1102","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993, 85(5):365-376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","DOI":"10.1093\/jnci\/85.5.365"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med, 2006, 166(10):1092-1097. https:\/\/doi.org\/10.1001\/archinte.166.10.1092","DOI":"10.1001\/archinte.166.10.1092"},{"key":"ref21","unstructured":"[22] B\u0103lteanu M, Kamal C, Kamal D, Postolache P, Tr\u0103istaru R. Pulmonary rehabilitation in COPD patients. Observational study. Med Surg J (Rev Med Chir Soc Med Nat Ia\u015fi), 2018, 122(3):474-483."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Spruit MA, Pitta F, McAuley E, ZuWallack RL, Nici L. Pulmonary rehabilitation and physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2015, 192(8):924-933. https:\/\/doi.org\/10.1164\/rccm.201505-0929CI","DOI":"10.1164\/rccm.201505-0929CI"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"[24] Gloeckl R, Marinov B, Pitta F. Practical recommendations for exercise training in patients with COPD. Eur Respir Rev, 2013, 22(128):178-186. https:\/\/doi.org\/10.1183\/09059180.00000513","DOI":"10.1183\/09059180.00000513"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Yang JCH, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TSK, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a Phase III study of Afatinib or Cisplatin\/Pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27):3342-3350. https:\/\/doi.org\/10.1200\/JCO.2012.46.1764","DOI":"10.1200\/JCO.2012.46.1764"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus Cisplatin plus Gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15(2):213-222. https:\/\/doi.org\/10.1016\/S1470-2045(13)70604-1","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Pecci F, Tarantino P. Patient-focused insights: how emotional distress shapes immunotherapy response in non-small cell lung cancer. Transl Lung Cancer Res, 2024, 13(12):3819-3823. https:\/\/doi.org\/10.21037\/tlcr-24-904","DOI":"10.21037\/tlcr-24-904"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Zeng Y, Hu CH, Li YZ, Zhou JS, Wang SX, Liu MD, Qiu ZH, Deng C, Ma F, Xia CF, Liang F, Peng YR, Liang AX, Shi SH, Yao SJ, Liu JQ, Xiao WJ, Lin XQ, Tian XY, Zhang YZ, Tian ZY, Zou JA, Li YS, Xiao CY, Xu T, Zhang XJ, Wang XP, Liu XL, Wu F. Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer. Nat Med, 2024, 30(6):1680-1688. https:\/\/doi.org\/10.1038\/s41591-024-02929-4","DOI":"10.1038\/s41591-024-02929-4"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Singh A, Kapoor A, Noronha V, Patil V, Menon N, Mahajan A, Janu A, Purandare N, Kaushal R, Prabhash K. ALK-positive advanced non-small cell lung cancer patients with poor performance status: outcomes in a real-world scenario. eCancerMedicalScience, 2022, 16:1407. https:\/\/doi.org\/10.3332\/ecancer.2022.1407","DOI":"10.3332\/ecancer.2022.1407"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Chau YF, Zhou H, Chen B, Ren H, Ma Z, Zhang X, Duan J. Screening for depression and anxiety in lung cancer patients: a real-world study using GAD-7 and HADS. Thorac Cancer, 2024, 15(13):1041-1049. https:\/\/doi.org\/10.1111\/1759-7714.15287","DOI":"10.1111\/1759-7714.15287"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I; WHO Panel. The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 Classification. J Thorac Oncol, 2015, 10(9):1243-1260. https:\/\/doi.org\/10.1097\/JTO.0000000000000630\"","DOI":"10.1097\/JTO.0000000000000630"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"link":[{"URL":"https:\/\/rjme.ro\/RJME\/resources\/files\/660425719726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:13:19Z","timestamp":1774865599000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/66\/4\/10\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.66.4.10","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}